Kronox Lab Sciences

Lot Size
1 Lot = 110 Qty
Min Investment
₹14960
Subscription
Oversubscribed
Listing Gain
15(Points)

IPO Details

Open Date
Jun 03, 2024
Close Date
Jun 05, 2024
Allotment Date
Jun 06, 2024
Allotment Date
Jun 06, 2024
Refund Initiation
Jun 07, 2024
Demat Transfer
Jun 07, 2024
Listing Date
Jun 10, 2024
Fresh Issue
0
Offer For Sale
130.15
Issue Price
₹129 to ₹136
Face Value
₹10
Issue Type
Fresh Issue
Total Issue Size
130.15 CR
QIB + NII Quota
50 + 15%
Retail Quota
35%
Listing On
NSE & BSE
Registrar
Link Intime India Pvt Ltd
Check Allotment Status

Company Financial Rusult In Crore

PERIOD ASSET REVENUE PROFIT
DRHP DRAFT

About Kronox Lab Sciences Company

Kronox Lab Sciences, incorporated in 2008, manufactures high-quality fine chemicals for diverse end-user industries. The company chemicals are used in various applications, such as manufacturing APIs, pharmaceutical formulation, scientific research, nutraceuticals, biotech applications, agrochemical formulations, personal care products, metal refineries, and animal health products. Kronox offers over 185 products, including phosphate, sulphate, acetate, chloride, citrate, nitrates, nitrites, carbonate, EDTA derivatives, hydroxide, succinate, gluconate, and others. It exports its products to countries such as the United States, Argentina, Mexico, Australia, Egypt, Spain, Turkey, UK, UAE, and China. Kronox had three manufacturing facilities in Vadodara, Gujarat near to the seaports of Mundra, Kandla, Hazira, and Nhava Sheva.

Know before investing

Strength

  • Wide range of products finding applications in diversified end-user industries.
  • High entry and exit barriers due to long customer approval cycles and strict product standards.

Risk

  • Products of the company are supplied in limited quantities and for specific use by application industries thus any change in the requirement of its products may affect the business.
  • The majority of sales of products are concentrated in industries viz. Pharmaceuticals and Scientific Research and Laboratory Testing.

Incorporated in 2008, Kronox Lab Sciences Limited is a manufacturer of high-purity speciality fine chemicals for diverse end-user industries. The company High Purity Specialty Fine Chemicals are used in various applications such as manufacturing APIs, pharmaceutical formulations, scientific research, nutraceuticals, biotech applications, agrochemical formulations, personal care products, metal refineries, and animal health products.

The company offers a wide range of over 185 products, including phosphate, sulphate, acetate, chloride, citrate, nitrates, nitrites, carbonate, EDTA derivatives, hydroxide, succinate, gluconate, and others. These products are supplied to customers in India and more than 20 countries worldwide.

The company exports its products to countries such as United States, Argentina, Mexico, Australia, Egypt, Spain, Turkey, United Kingdom, Belgium, United Arab Emirates, China, among others.

The company has three manufacturing facilities in Vadodara, Gujarat, close to the seaports of Mundra, Kandla, Hazira, and Nhava Sheva. The facilities cover 17,454 sq. m. and have an installed capacity of 7,242 TPA as of December 31, 2023. Unit I/II holds FSSC 22000 (Version 5), ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 certifications. Additionally, some products manufactured at Unit I have obtained Kosher, Halal, GMP, and GLP certifications.

As of December 31, 2023, the company is conducting research and development on 122 products.

The company has served over 592 customers in the past three years. By December 31, 2023, 141 customers of the total, placed repeat orders.

As of December 31, 2023, the company employees 212 people at various levels.

 

DISCLAIMER: None of the financial information published herein should be construed as an offer to buy or sell securities or as advice in any way. All information published herein is for educational and informational purposes only and should not be relied upon as a basis for investment decisions under any circumstances. Readers must consult a qualified financial advisor before making any actual investment decisions based on the information published herein. Any reader who makes decisions based on the information published herein does so solely at his or her own risk. Investors should be aware that any investment in equity markets is subject to unpredictable market-related risks. The author does not intend to invest in this offering.